Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $43.99M rose 62.3% year over year, ahead of the +52.6% change in trailing-twelve-month operating expenses. Sequentially, it rose 15.0% from the prior quarter. Over 3 fiscal years it compounded at +129.5% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +62.3% holds above the trailing-twelve-month pace of +52.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 125.1M USD
- Year-over-year change
- +52.2%
- 3-year CAGR
- +129.5%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 125.1M | +52.2% |
| FY2024 | 2024-12-31 | 82.22M | +128.0% |
| FY2023 | 2023-12-31 | 36.07M | +248.4% |
| FY2022 | 2022-12-31 | 10.35M | — |
Operating Expenses vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's LTM Mar 2026 operating expenses of $141.71M is the 6th highest of the 10 companies compared; the peer median is $209.6M.
- Its year-over-year change of +52.6% is the 4th highest of 9, against a peer median of +36.3%.
- Operating expenses amounts to 708.6% of revenue for RAPP, versus a peer median of 100.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1B | +38.7% | +6.3% | 83.2% | |
| LTM Jun 2026 | $912.58M | +33.9% | +50.1% | 117.5% | |
| LTM Sep 2026 | $329.22M | +502.1% | +75.3% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $218.08M | -20.5% | +20.2% | — |
| LTM Mar 2026 | $209.6M | +141.3% | +76.5% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $141.71M | +52.6% | +129.5% | 708.6% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $66.77M | +256.3% | +44.2% | — |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $46.78M | — | +121.2% | — |
| LTM Mar 2026 | $42.71M | -20.4% | +3.3% | — | |
| LTM Mar 2026 | -$55.19M | -179.1% | +31.6% | — | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $209.6M | +36.3% | +44.2% | 100.4% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 15K | 112K | 839K | 1.02M |
| Gross Profit | (15K) | (112K) | (839K) | (1.02M) |
| Gross Margin | — | — | — | — |
| Research & Development | 9.12M | 28M | 60.94M | 94.79M |
| Selling, General & Admin | 1.37M | 8.07M | 22.12M | 30.31M |
| Operating Expenses | 10.35M | 36.07M | 82.22M | 125.1M |
| Depreciation & Amortization | 15K | 112K | 839K | 1.02M |
| EBITDA | (10.35M) | (34.66M) | (77.47M) | (124.08M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (10.37M) | (36.18M) | (83.06M) | (125.1M) |
| Operating Margin | — | — | — | — |
| Interest Income | 0 | 2.53M | 12.14M | 13.62M |
| Interest Expense | 285K | 0 | 0 | 0 |
| Other Income / Expenses | (285K) | 1.4M | 4.75M | 13.62M |
| Income Before Tax | (10.65M) | (34.78M) | (78.31M) | (111.48M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 10K | 0 | 0 |
| Net Income | (10.65M) | (34.79M) | (78.31M) | (111.48M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.29) | (0.95) | (3.78) | (2.86) |
| EPS (Diluted) | (0.29) | (0.95) | (3.78) | (2.86) |
| Weighted Avg Shares | 20.12M | 18.08M | 20.74M | 46.98M |
| Weighted Avg Shares (Diluted) | 20.12M | 18.08M | 20.74M | 46.98M |
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.